Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines  by Lockyer, Kay et al.
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a  b  s  t  r  a  c  t
An  analysis  of  structure-antibody  recognition  relationships  in nine  licenced  polysaccharide-tetanus  tox-
oid (TT) conjugate  vaccines  was  performed.  The  panel  of  conjugates  used  included  vaccine  components
to  protect  against  disease  caused  by  Haemophilus  inﬂuenzae  type  b, Neisseria  meningitidis  groups  A,  C, W
and  Y and  Streptococcus  pneumoniae  serotype  18C.  Conformation  and  structural  analysis  included  size
exclusion  chromatography  with  multi-angle  light  scattering  to  determine  size, and  intrinsic  ﬂuorescence
spectroscopy  and  ﬂuorescence  quenching  to evaluate  the protein  folding  and  exposure  of  Trp residues.
A  capture  ELISA  measured  the  recognition  of  TT epitopes  in the  conjugates,  using  four  rat  monoclonal
antibodies:  2 localised  to  the  HC domain,  and  2 of which  were  holotoxoid  conformation-dependent.  The
conjugates  had  a wide  range  of average  molecular  masses  ranging  from  1.8  × 106 g/mol  to  larger  than
20  × 106 g/mol.  The  panel  of conjugates  were  found  to be well  folded,  and  did  not  have spectral  features
typical  of aggregated  TT.  A partial  correlation  was  found  between  molecular  mass  and  epitope  recog-
nition.  Recognition  of  the  epitopes  either  on  the  HC domain  or the  whole  toxoid  was  not  necessarily
hampered  by  the size  of  the  molecule.  Correlation  was also  found  between  the  accessibility  of  Trp  side
chains  and  polysaccharide  loading,  suggesting  also  that  a higher  level  of  conjugated  PS  does  not  neces-
sarily  interfere  with  toxoid  accessibility.  There  were  different  levels  of carrier  protein  Trp  side-chain  and
epitope  accessibility  that  were  localised  to  the  HC domain;  these  were  related  to the  saccharide  type,
despite  the  conjugates  being  independently  manufactured.  These  ﬁndings  extend  our understanding  of
the molecular  basis  for  carrier  protein  recognition  in  TT  conjugate  vaccines.
ht  © 2Crown  Copyrig
. Introduction
The global burden of bacterial meningitis is primarily due
o invasive infection by Neisseria meningitidis and Streptococcus
neumonia. Haemophilus inﬂuenzae serogroup B (Hib) accounted
or many cases of bacterial meningitis in the developed world
rior to the introduction of the Hib conjugate vaccine in 1987.
ib vaccines have reduced incidence of disease attributed to
ib by 80% or more, dependent on vaccine uptake [1,2]. Mono-
alent meningococcal group C (MenC) vaccines, licenced in
999–2000, have reduced the incidence of invasive meningococ-
al disease caused by MenC by over 90% in the UK [3,4]. There
re currently three licensed tetravalent meningococcal conjugate
accines, which also offer protection from serotypes A, W and Y [5],
nd pneumococcal conjugate vaccines can protect against up to 13
∗ Corresponding author. Tel.: +44 1707 641 209; fax: +44 1707 641 054.
E-mail address: barbara.bolgiano@nibsc.org (B. Bolgiano).
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disease-causing serotypes [6,7]. The signiﬁcant mortality rates and
long-term sequelae following infection by encapsulated bacteria
have made such vaccination strategies highly sought after world-
wide.
Conjugate vaccines have puriﬁed oligo- or polysaccharide (PS)
covalently linked to a carrier protein, e.g. tetanus toxoid (TT), in a
process known as conjugation. A conjugate vaccine elicits a T-cell
dependent antibody response, leading to high-avidity, circulating
antibodies and the establishment of immune memory in infants
and other at-risk groups, which are not evoked by plain PS vac-
cines [4]. The failure of plain PS vaccines to elicit IgG memory in
mice has led to the belief that elicitation of T-cell help by glycocon-
jugates was  attributable to MHC  Class II presentation of peptides to
the T-cell receptor. Carbohydrates fail to directly bind MHC  Class
II receptor molecules and are not presented to T-cells, and are,
therefore, truly ‘T-cell independent’ [8]. The 2011 study carried out
by Avci et al. [8] has demonstrated that MHC  Class II-presented
glycopeptides elicit T-cell help; glycoconjugated carbohydrates are
processed into smaller glycans which are presented to the T-cell
 is an open access article under the CC BY-NC-ND license
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eceptor on the APC surface. Carbohydrate epitope presentation
o CD4+ cells plays a vital role in inducing polysaccharide-speciﬁc
daptive immune responses. A separate study suggested that the
arbohydrate component of a pneumococcal glycoconjugate is pre-
ented to the APC surface and co-localises with the MHC  class II
rotein [9].
Glycoconjugate vaccines vary immensely due to biological vari-
tions such as polysaccharide type and chemical variations such as
onjugation chemistry. These factors as well as the choice of car-
ier protein can provide glycoconjugate vaccines varying in terms
f both size and structure. The size of the conjugate can depend on
he oligomeric state (and monomeric size) of the carrier protein, the
hain-length of the PS, the saccharide-to-protein loading and the
onjugation chemistry used [2,10]. Previous studies have suggested
hat the immunogenicity of conjugate vaccines is partly depend-
nt on their PS chain length and structural properties [11–13], as
ell as the intrinsic properties of the carrier protein, but studies
ave not been done to survey the protein epitope accessibility. In
his study, a comparison of the protein structural and antibody
ecognition features of a panel of polysaccharide-tetanus toxoid
onjugate vaccines has been undertaken to determine if the acces-
ibility of the exposed TT epitopes is affected by high PS loading in
olysaccharide-TT conjugates.
. Materials and methods
.1. Vaccines
A panel of nine glycoconjugates manufactured with TT as car-
ier protein by a variety of manufacturers was obtained. The panel
ncluded Hib-TT-A and Hib-TT-B (coded as described by Ho et al.
14]; two MenC-TT conjugates and two MenA-TT conjugates (arbi-
rary codes were assigned); and, one of each of the following
onjugates; MenW-TT, MenY-TT and Pneumo 18C-TT. The bulk
uriﬁed carrier protein conjugated to MenC-TT (2), MenW-TT and
enY-TT was also included in the panel.
Prior to analysis, samples of bulk intermediate polysaccharide-
rotein conjugates supplied by vaccine manufacturers were
ialysed at 4 ◦C with three changes of phosphate buffered saline
PBS ‘A’) (10.1 mM Na2HPO4, 1.84 mM KH2PO4, 171 mM NaCl, 3 mM
Cl pH 7.3–7.5) for 24–26 h using dialysis membranes with a
0 kDa-molecular-mass cut-off pore size (Spectra/Por® 7 Dialysis
embrane, Spectrum Laboratories Inc., Rancho Dominguez, CA,
SA).
Polysaccharide loading ratios of mol  polysaccharide repeating
nit: mol  tetanus toxoid monomeric unit were converted from the
 PS:g ratios determined by the manufacturers.
.2. Monoclonal antibodies
Four rat IgG monoclonal antibodies, TT04, TT07, TT08 and TT10,
gainst tetanus toxoid were produced from rat hybridoma cell lines,
rovided by Wellcome Research Laboratories (Beckenham, U.K.).
he hybridomas were prepared [15] and the antibodies charac-
erised [15,16] as described previously.
.3. Determination of protein content
For TT conjugates, protein concentration was determined using
 molar absorption coefﬁcient, A278 nm, 0.1% of 1.229 cm−1 mg−1 ml
or TT [17]. Samples were analysed on a Perkin–Elmer Lambda 800
V-VIS spectrophotometer. A data increment of 0.50 nm was used,
can speed was 125 nm/min, slit width was 1.00 nm and integration
ime was 0.24 s. A cell volume of 1.0 ml  with 10 mm path-length
as used. Following determination of protein concentration, the
amples were diluted in PBS ‘A’ to 500 g protein/ml, where3 (2015) 1345–1352
possible, for SEC-MALS and 6–25 g protein/ml for ﬂuorescence
spectroscopy.
2.4. Determination of dn/dc
The speciﬁc refractive increment, dn/dc,  was measured using
an interferometric refractometer (Optilab rEX; Wyatt Technol-
ogy Corp. Santa Barbara, CA, U.S.A.) which had been calibrated
with ﬁve different concentrations of BSA in PBS ‘A’, ranging from
0.25 to 2.0 mg/ml. A series of ﬁve different sample concentrations
ranging from 0.05 to 1.0 total mg/ml  [(mg of saccharide + mg of pro-
tein)/ml, for conjugates], was  prepared from dialysed sample and
syringed through the refractometer, which had been equilibrated
with ﬁltered dialysis buffer, starting with the lowest concentration.
For conjugate samples, the saccharide and protein concentrations
were added together to give the sample concentration, c (mg/ml).
dn/dc values (ml/g) were calculated using the software supplied by
the manufacturer (DNDCTM; Wyatt Technology Corp.). Percentage
errors were determined by the Astra software as a combination
of noise for each detector combined with the quality of the line
projected [18].
2.5. Molecular sizing by SEC/MALS
The HPLC-SEC/MALS system consisted of a gradient pump
(Thermo Fisher (Dionex) UK Ltd., Hemel Hempstead, UK) and
autosampler ﬁtted with a 200 l injection loop. A Tosoh Bioscience
TSK PWXL guard column and TSK gel G6000PWXL + G5000PWXL ana-
lytical columns were connected in series. Chromatographic signals
were collected by an ICS series multi-wavelength UV detector
(Thermo Fisher UK Ltd.) an interferometric refractometer (Wyatt
Technology Corp., Santa Barbara, USA) and a DAWN-EOS 18-angle
angle light scattering detector (Wyatt Technology Corp.). PBS ‘A’
ultra-ﬁltered through 0.10 m Millipore ﬁlter was used as eluent at
a ﬂow rate of 0.25 ml/min. Fifty g protein (500 g/ml where pos-
sible) was injected per sample and total mg protein + mg  saccharide
(by calculation) were used for subsequent calculations.
Data from 11 detectors between the angles of 57.0◦ and 141.0◦
were used and weight-average molar mass and % recoveries were
determined using Astra for Windows 5.3.4TM software from Wyatt
Technology Corp. The dn/dc values determined for each conju-
gate/carrier protein (Table 1) were used in calculations, with the
exception of two different MenA-TT conjugates which gave unusu-
ally low dn/dc values. For these a dn/dc value of 0.191 ml/g was
used [19]. The weight-average molecular mass (Mw) and polydis-
persity (Mw/Mn)  were determined by the Zimm method and were
obtained for high molar mass (peak 1), lower molar mass (peak
2) and total combined peak data (peak 3), also used for the pur-
pose of determining the % recovery. Errors are calculated by the
Astra software in the same way as described for the refractive index
calculation.
2.6. Fluorescence spectroscopy
Intrinsic ﬂuorescence spectra were obtained on a Horiba Jobin
Yvon FluoroMax-4 spectroﬂuorometer in 1 ml,  1 cm path-length
quartz cells. Excitation wavelengths (ex) of both 280 and 295 nm
were used, with a band pass of 4.25 nm for excitation and emission
monochromators and data was collected at increments of 0.5 nm.
Emission spectra were collected using a wavelength range from
260 to 550 nm (280 nm excitation) or from 275 to 550 nm (295 nm
excitation). Fluorescence spectra were corrected by subtracting the
corresponding base-line spectra of buffer alone (PBS ‘A’). Sam-
ples of 6–25 g protein/ml in PBS ‘A’ were used. Fluorescence
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Table  1
SEC/MALLS-determined molar mass values of TT conjugates.
Sample PS/protein,a mol:mol dn/dc,b ml/g Peak 1 Peak 2 Total Peak 3
Mean Mw,d
g/mol ×106
Mean Mw,
g/mol ×106
Mean Mw,
g/mol ×106
Polydispersity,
Mw/Mn
TT No PS present 0.155 (3%) 0.216 (2%) 0.130 (1%) 0.155 (2%) 1.0
Hib-TT-A 193 0.174 (1%) 18.3 (1%) 5.54 (0%) 7.16 (1%) 1.4
Hib-TT-B 178 0.189 (0%) 15.3 (1%) 4.39 (1%) 2.60 (1%) 1.5
MenA-TT (1) 575 0.191c 4.97 (5%) 0.929 (4%) 2.76 (5%) 2.3
MenA-TT (2) 209 0.191c 8.81 (6%) 3.03 (6%) 5.05 (6%) 1.4
MenC-TT (1) 414 0.166 (1%) 2.90 (0%) 0.829 (1%) 1.84 (1%) 1.6
MenC-TT (2) 517 0.212 (3%) 9.22 (1%) 3.87 (1%) 5.04 (1%) 1.2
MenW-TT 284 0.196 (1%) 21.6 (5%) 7.93 (1%) 11.5 (2%) 1.3
MenY-TT 302 0.209 (1%) 19.0 (4%) 10.5 (1%) 13.5 (2%) 1.1
Pneumo 18C-TT 84 0.153 (2%) 17.9 (1%) 6.54 (1%) 7.81 (1%) 1.6
a PS: protein (mol:mol) values were converted from g:g values as quoted by the manufacturer.
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c A dn/dc value of 0.191 ml/g [19] was used for the MenA-TT conjugates.
d Values in parentheses are the percent error for molar mass measurements and 
mission wavelength maxima (Fmax) values were determined using
he FluorEssence software and are accurate to ±0.5 nm.
.7. Fluorescence quenching
Fluorescence quenching was carried out from measurements
btained using an excitation wavelength of 295 nm.  The same
arameters were used as for the intrinsic ﬂuorescence measure-
ents. Aliquots of a 5 M stock acrylamide (Sigma–Aldrich, UK,
9099) was added at concentrations ranging from 0.05 M to 0.83 M
o initial 1 ml  samples of TT or conjugate (12.5 g protein/ml) in
BS ‘A’ and emission data was collected between 305 and 420 nm.
 Peltier device was used to keep the solution at 25 ◦C. Spectra
ere corrected by subtracting the corresponding base-line spectra
f PBS for each acrylamide concentration, and for volume adjust-
ents. The Fo/F ratio was calculated where Fo is the height at the
aximal ﬂuorescence signal (cps) at Fmax for the sample with no
crylamide addition, and F is the height at Fmax for the sample at
ach acrylamide concentration. Stern–Volmer plots were used to
etermine the linearity of each quenching curve, with Fo/F ratio
lotted against quencher concentration. The slope, equal to the
tern–Volmer quenching constant (KSV), Y-intercept and R2 were
lso determined.
.8. ELISA
A capture ELISA was used to detect of the recognition of TT
pitopes in the conjugates by rat monoclonal anti-tetanus tox-
id antibodies, TT04, TT07, TT08, TT10 [15,16] as per the method
sed by Coombes et al. [20]. ELISA plates were coated overnight
t 4 ◦C with 100 l/well of an anti-tetanus monoclonal antibody
5 g/ml), diluted in carbonate buffer (0.05 M,  pH 9.6). The plates
ere washed (3×)  by immersion in phosphate buffered saline
pH 7.4) containing 0.05% (vol/vol) Tween 20 (PBST), then blocked
ith 150 l/well of PBST containing 2.5% (wt/vol) dried skimmed
ilk powder (PBSTM) for 1 h at 37 ◦C. Following a second wash in
BST, serial two-fold dilutions of the tetanus toxoid or bulk conju-
ate samples, at the same protein concentration, in PBSTM were
repared in the plate (ﬁnal volume 100 l ranging from 1.5 g
T to 0.01 g TT) and the plates were incubated at 37 ◦C for 2 h.
lates were washed as described previously and 100 l/well of
uinea pig anti-tetanus IgG, diluted in PBSTM, was  added for 2 h at
7 ◦C. After further washing, antigen-speciﬁc IgG antibodies were
etected using 100 l/well of HRP-conjugated goat anti-guinea pig
gG diluted 1/2000 in PBSTM. After a further incubation of 1 h at
7 ◦C and a ﬁnal wash, 100 l/well of substrate solution containing
.5 mg/ml  ABTS and 0.008% (vol/vol) hydrogen peroxide in 0.05 Me ±values.
alues.
citric acid buffer (pH 4) were added. The reaction was allowed to
develop at room temperature for up to 30 min  and the optical den-
sity was  measured at 405 nm using a Multiskan ELISA plate reader
(Thermo Life Sciences, UK). Epitope recognition was  calculated rel-
ative to the reference toxoid by parallel line analysis (log optical
density vs. log dose), using a minimum of 3 sequential points from
the linear section of the dose response curve for the reference and
test sample, and expressed in Lf/ml using Combistats software,
which was converted to g TT/ml. Analysis of variance was used
to test for any signiﬁcant deviation from linearity or parallelism of
the dose response relationship (p < 0.01).
3. Results
3.1. Molecular sizing and dn/dc determination of tetanus toxoid
conjugates
A wide range of sizes were found for the conjugates, with
weight-average molecular mass (Mw)  values for the total com-
bined peak area ranging from 1.8 × 106 g/mol to greater than
20.0 × 106 g/mol (Table 1 and Fig. 1). All of the TT conjugates were
polydisperse as previously observed [19,21–23] with Mw/Mn  up to
2.3.
The TT sample was found to have a Mw  of 155,000 g/mol, which
is in agreement with previously determined SEC/MALS [19,23,24]
and sedimentation equilibrium [24] values. A peak due to dimer-
ization was seen, as expected [24,25]. Following conjugation there
were increases in the molecular mass of the samples, as expected.
All conjugates eluted with broad asymmetric peak(s), as expected
for the polydisperse samples (Fig. 1). Signiﬁcantly different sizes
(Mw) were determined for the high and low molar mass peak areas,
Peaks 1 and 2, respectively (Table 1), suggesting the presence of
conjugate oligomers. The elution time of the conjugates was related
to their SEC/MALS-determined sizes (Fig. S1), except for Hib-TT-A,
which eluted relatively later. MenW and MenY conjugates were
the largest conjugates, and MenC-TT (1) and MenA-TT (1) were the
smallest.
The calculated recoveries based on the dn/dc values and RI sig-
nals were generally between 50 and 80%, with the larger conjugates
generally having the lower recoveries than the smaller conjugates.
Aggregates of up to 109–1010 g/mol, the limit of the MALS, are easily
detected by the light scattering signal, even at low concentration
when UV and RI signals are diminished. The chromatography and
column conditions do allow for the detection of aggregates at Vo,
but these were not signiﬁcant (>5%) in the samples evaluated. There
was no overall correlation between the mass (Mw) and PS loading
(Fig. 2A).
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Fig. 1. Size exclusion chromatograms showing RI signal ( ), 90◦ LS signal ( ) and UV 280 nm signal ( ): MenC-TT (1) (A), MenC-TT (2) (B), MenW-TT (C),
M (A) (I)
2
3
a
s
r
oenY-TT (D), MenA-TT (1) (E), MenA-TT (2) (F), Pneumo 18C-TT (G), TT (H), Hib-TT
 and peak 3.
.2. Tetanus toxoid conformation in conjugates
Tetanus toxoid conformation is considered to be a good char-
cteristic of vaccine quality [26], although there is no evidence
uggesting that maintenance of native-like conformation is a
equirement for its immunogenicity and protection. Intrinsic ﬂu-
rescence spectroscopy has been used to differentiate between TT and Hib-TT(B) (J). The vertical bars indicate the integration limits for peak 1, peak
conformers through the spectral features of its aromatic amino acid
side-chains [14,27–29]. Of the total 1315 amino acids that the par-
ent toxin contains, there are 56 phenylalanine residues, 79 tyrosine
(Tyr) residues and 13 tryptophan (Trp) residues [30]. An excita-
tion wavelength of 280 nm gives an emission spectrum which is
sensitive to the solvent exposure of side-chains of Trp and to a
lesser extent Tyr, while ex of 295 nm is used to obtain spectra
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Table  2
Intrinsic ﬂuorescence maximum values and quenching of TT conjugates.
Sample Fmax(ex = 280 nm)  Fmax(ex = 295 nm)  KSV Intercept R2 Curve type
TTa 330.5 334.0 2.25 1.08 0.993 Linear
Hib-TT-A 331.0 335.5 2.75 1.09 0.990 Linear
Hib-TT-B 331.0 332.5 2.15 1.09 0.992 Linear
MenA-TT (1) 329.0 335.5 2.78 1.16 0.978 Upward
MenA-TT (2) 329.5 335.5 2.48 1.01 1.00 Linear
MenC-TT (1) 331.5 335.5 4.24 1.32 0.877 Downward
MenC-TT (2) 330.5 333.5 3.01 0.96 0.993 Linear
MenW-TT 330.0 333.5 2.69 1.07 0.988 Linear
MenY-TT 332.0 335.5 2.87 1.10 0.985 Linear
Pneumo 18C-TT 329.0 334.0 2.26 1.10 0.977 Downward
Ref.b
TT (Hib-TT-A) 329 333 14
TT  (Hib-TT-B) 327 331 14
TT  (MenA-TT 1) 328 333
TT (MenC-TT 1) 328 333 14
es.
a
p
r
s
a
a
o
w
d
f
1
t
F
Sa TT used in the production of MenC (2), MenW,  MenY and Pneumo 18C conjugat
b The Fmax values obtained in separate experiments.
lmost exclusively due to Trp. Changes in the conformation of a
rotein arising from Trp side-chain movements can be tracked by
ed-shifts, i.e. to longer max, upon protein unfolding and expo-
ure of the side-chains; and by blue-shifts, i.e. to shorter max upon
ggregation and internalisation of the residues, which are usually
ccompanied by a decrease in ﬂuorescence intensity.
The TT carrier protein used in this study, had Fmax values
f 330.5 nm (ex = 280 nm)  and 334.0 (ex = 295 nm), which were
ithin 3.5 nm of those previously published [14,27,28] toxoids pro-
uced by different manufacturers (duration and concentration of
ormaldehyde) or manufacturing sites (Table 2). Not more than
 nm difference was seen between different batches of the same
oxoid.
ig. 2. Relationship between PS/protein loading and mean molar mass (A) and
tern–Volmer quenching constant and PS/protein loading (B) for TT conjugates.The conjugate panel had Fmax values ranging from 329 to
332 nm when excited at 280 nm,  and 332.5–334 nm, when excited
at 295 nm (Table 2 and Fig. S2). There was  a 1.5 nm red-shift in Fmax
of TT residues following conjugation to MenC (2) and MenY, which
may  indicate that some protein unfolding had occurred from conju-
gation. There was  no signiﬁcant change in TT ﬂuorescence emission
following conjugation of MenW,  however.
Comparison of the intrinsic ﬂuorescence data of the toxoids
with their ‘matching’ conjugate, shows that overall, there is little
difference between the Fmax of TT prior to and following conju-
gation, relative to changes observed in chaotropic agent-induced
unfolding experiments [28,29], indicating that conjugation of the
TT monomer to the saccharide chains results in very little change in
its conformation, as observed previously by optical spectroscopic
studies for both Hib-TT and MenC-TT (1) conjugates [14]. Following
conjugation there is a red-shift for all conjugates, with the excep-
tion of a 1 nm blue-shift (280 nm excitation only) for MenA-TT (2),
and a 0.5 nm blue-shift (295 nm excitation only) for MenC-TT (2), W
and Y. Fluorescence emission spectra recorded at 280 and 295 nm
are dependent on different groups of amino acids, so it would not
be expected that the changes would be identical.
This structural stability has been attributed to the
formaldehyde-induced cross-linking that occurs during the
detoxiﬁcation stage of its manufacture. There was no spectral
evidence of aggregated TT, as characterised by blue-shifted Fmax
and lower intensity spectra (Fig. S2).
Fluorescence quenching was  used to determine the degree of
accessibility of Trp residues to the uncharged quencher, acryla-
mide. Using the Stern–Volmer relationship expressed as KSV, which
relates ﬂuorescence yield of the sample to the concentration of the
added quencher, a linear relationship with an intercept of 1 was
typically found. All the conjugates displayed a linear relationship
(R2 ≥ 0.98) except MenA-TT (1), which had upward curvature, and
MenC-TT (1) and Pneumo 18C-TT, which had downward curva-
tures in Stern–Volmer analysis (Figs. S3 and S4). The conjugates
displaying linear curve types had similar gradients KSV of 2.15
to 3.01 (Table 2) indicating that the chromophores are equally
accessible to the quencher in those conjugated molecules. Both
MenC-TT conjugates have comparatively high KSV values indicat-
ing that Trp residues are more exposed to the quencher in these
conjugates. The deviation from linearity seen with three of the con-
jugates could indicate that the quencher causes a perturbation in
structure with increasing concentration, leading to a change in the
Trp accessibility, and a positive or negative co-operativity arising
from internal energy transfer (Trp-to-Trp ﬂuorescence quenching
and emission). Some acrylamide solutions contain acrylic acid as
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Table 3
TT epitope recognition determined by monoclonal antibodies.
mAb sample TT content, g/ml (95% C.I.)
TT04a TT07 TT08 TT010
TT 299.51 (248.06, 362.17) 972.15 (850.63, 1114.10) 445.58 (428.40, 463.34) 255.46 (231.54, 282.15)
Hib-TT-A 1.15 (0.95, 1.38) 1.09 (0.95, 1.26) NP 2.73 (2.44, 3.04)
Hib-TT-B 1.55 (1.28, 1.87) 11.12 (10.00, 12.36) NP 4.23 (3.79, 4.72)
MenA-TT (1) 32.01 (26.52, 38.74) 10.92 (9.70, 12.32) 99.76 (95.93, 103.73) 14.31 (12.84, 15.95)
MenA-TT (2) 1.89 (1.51, 2.33) 9.70 (8.73, 10.79) NP 4.26 (3.86, 4.70)
MenC-TT (1) 8.07 (6.68, 9.80) 22.26 (20.02, 24.74) 14.01 (13.56, 14.57) 6.81 (6.12, 7.60)
MenC-TT (2) 7.92 (6.56, 9.59) 46.61 (40.97, 53.07) 34.55 (33.19, 35.95) 8.85 (7.92, 9.87)
MenW-TT 16.21 (14.94, 17.63) 33.76 (24.82, 45.59) 156.40 (130.52, 191.37) 15.99 (14.80, 17.27)
MenY-TT 18.67 (17.14, 20.35) 108.02 (80.10, 128.76) 97.73 (82.13, 116.86) 12.84 (11.92, 13.83)
Pneumo 18C-TT 22.93 (21.06, 24.97) 83.04 (62.89, 112.54) 73.64 (61.83, 87.65) 20.35 (18.93, 21.85)
N
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w
s
d
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w
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r
t
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l
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9P: Not parallel and statistically invalid.
a Values in parentheses are statistical error using a 95% conﬁdence interval.
 contaminant; however it is unlikely that this is the cause as the
crylamide reagent used had a purity of 99.9%. A weak correlation
as found between PS loading and Stern–Volmer quenching con-
tant (r = 0.54), which increased (r = 0.71), when the 3 conjugates
emonstrating non-linear behaviour were excluded (Fig. 2B).
.3. Epitope recognition by monoclonal Abs to tetanus toxoid
The accessibility of epitopes on the conjugated TT molecules
ere evaluated with four rat monoclonal IgG antibodies made
gainst toxoid, which are capable of recognising toxin and toxoid.
he epitopes deﬁned by mAbs, TT04 and TT10, are linear epitopes
ocated on the C fragment of the heavy chain of tetanus toxin, also
eferred to the cell-binding, or HC domain, with TT10 being able
o neutralise toxicity in mice [15,16]. Epitopes deﬁned by TT07 and
ig. 3. Relationship between epitope binding to TT conjugates and conjugate size.
onjugate size is deﬁned by panel (A) Molar Mass (Mw) and panel (B) PS/protein
oading. The monoclonal antibodies used were: TT04 ( ), TT10 ( ), TT07 ( ) and
T08 (). Conjugates in panel (A) are 1, MenC-TT(1); 2, Hib-TT(B); 3, MenA-TT(1);
,  MenC-TT (2); 5, MenA-TT (2); 6, Hib-TT(A); 7, Pneumo 18C-TT; 8, MenW-TT; and
,  MenY-TT.TT08 are dependent on the tertiary structure of the intact toxin and
are conformational epitopes [15].
The TT carrier protein alone was  recognised by all mAbs with
the highest epitope recognition by the ‘conformational’ antibodies,
TT07 and TT08 (Table 3). The epitope recognition of the conjugated
TTs was  10–50-fold lower. Interestingly, the Hib conjugates gen-
erated similar results to each other, as did the MenC conjugates,
and the structurally similar MenW and Y conjugates, with similar
binding by TT04 and TT10 to the conjugate pairs. The size-variant
MenA conjugates were not comparable; the smaller MenA-TT (1)
showed a higher degree of epitope recognition than MenA-TT (2)
particularly for the linear epitopes. The phosphodiester-containing
Hib and MenA (2) – conjugated TT samples gave the lowest binding,
and could have been affected by the phosphate in the assay buffer.
Only a partial correlation, at best, was found between conjugate
size (Mw)  and epitope binding by the linear HC mAbs, TT04 (r = 0.23)
Fig. 4. Ribbon backbone structures of tetanus toxoid domains. (A) Catalytic domain
of  tetanus toxin (PDB accession 1YVG). The single Trp in the structure is highlighted
[31]. (B) HC domain of tetanus toxin (PDB accession 1DLL). All Trp residues are well
buried, with the exception of one (Trp1289) [32].
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nd T10 (r = 0.45), although the binding of these mAbs did show an
ncreased correlation with PS loading (r = 0.52 and 0.68 for TT04 and
T10, respectively), when Pneumo 18C-TT was excluded. A positive
orrelation between size and the ability of conformational mAbs to
ind conjugated TTs was  seen for TT07 (r = 0.67) and TT08 (r = 0.68)
Fig. 3A and B).
. Discussion
Polysaccharide-protein conjugate vaccines that protect against
arriage and infection of encapsulated bacteria are regarded as
ell-deﬁned, puriﬁed subunit vaccines. Yet, little has yet been
eported on the accessibility of key protein epitopes that might
erve as the glycopeptide epitopes presented to antigen-presenting
ells in its role as a carrier protein, or even as protective toxin
eutralising epitopes. In this study, the structural features of nine
ifferent polysaccharide – tetanus toxoid conjugates comprising
 different PS structural types, all components of commercially
icenced vaccines, were compared using physico-chemical meth-
ds. An evaluation of their size, carrier protein conformation, and
pitope binding was performed in order to correlate structural fea-
ures with epitope recognition in the context of conjugated tetanus
oxoid.
All TT conjugates were found to be polydisperse with
espect to size, and contained subpopulations ranging from 1
o > 20 × 106 g/mol. The conjugated toxoids were found to be well-
olded, and did not have spectral features typical of aggregated
T.
The structural conformation of the TTs was evaluated through
ntrinsic protein ﬂuorescence which uses primarily Trp side-chains
s markers. In order to localise the Trp side-chains with respect
o the three-dimensional structure, the L-chain (catalytic domain)
nd the HC structures were used, as a crystal structure for full-
ength tetanus toxin is not available. The L-chain contains only a
ingle Trp is at position 43 of the sequence which forms part of -
trand with regards to its secondary structure (Fig. 4A) [31], and it
s unlikely to contribute greatly to the ﬂuorescence signal observed.
he H-chain contains the remaining 12 Trp residues from position
15 to 1312, with 9 of these being in the HC domain. The majority
f these Trp residues are well buried in the hydrophobic core of
he HC domain (Fig. 4B) [32], indicating that the majority ﬂuores-
ence signal comes from this part of the tetanus toxin/toxoid. The
C domain is a key part of the molecule with respect to immuno-
enicity in that it contains the toxin neutralising epitopes of the
olecule [15,33] and potent T-cell universal epitopes [34]. The Hc
omain also contains the neuronal cell ganglioside binding sites
or receptor binding activity [32] and forms stable dimers via an
ntermolecular bond [35].
Correlation was found between the PS loading (moles saccha-
ide: moles TT) with acrylamide quenching of TT, suggesting that
igh ratios of negatively charged conjugated PS (ranging from 100
o 600 moles PS/mol TT) did not interfere with tetanus toxoid tryp-
ophan amino acid side-chain interaction. Likewise, the recognition
f epitopes on the Hc domain or the holotoxoid was  not necessarily
ampered by the size of the molecule or the extent of PS loading; in
act, positive correlations were found between epitope recognition
nd molecular mass and/or PS loading. Considering the diversity
f conjugation chemistries used to manufacture these molecules,
t was intriguing that ‘serogroup’-speciﬁc patterns were identiﬁed.
ll the TT conjugates studied here were manufactured with TT that
ad been puriﬁed of aggregates prior to conjugation.
It should be recognised that the conjugates did, in fact, have
igniﬁcantly lower binding to the mAbs than did the carrier pro-
ein alone, and this as well as the speciﬁc conjugation sites may
lay a role in their immune response. The conformational mAbs3 (2015) 1345–1352 1351
gave strongest evidence that larger conjugates which are likely to
contain the networks of oligomeric carrier proteins described by
Egan [36], actually have more accessible carrier protein. It has been
hypothesised that the asymmetric, elongated structure of TT found
by Abdehameed et al. [24] may  provide the necessary surface area
for conjugation. Such an elongated surface structure was  also found
by small angle X-ray scattering of the HC domain [35]. The mAbs
recognising the linear epitopes of the HC domain, one of which
deﬁnes a protective neutralising epitope, also showed a preference
for binding TT molecules with higher PS loading.
Relatively few models for proteolytic processing of conjugate
vaccine molecules following uptake by antigen presenting cells
have been substantiated. Our understanding of what deﬁnes effec-
tive glycoprotein T-cell immunogens to provide the initial, critical
stimulation of T- and B-cell responses are based on theoretical
knowledge of the lower threshold limits for carbohydrate repeat-
ing units [37] and polypeptide compositional binding to MHC  [38],
as well as the identity of naturally processed peptides of TT [34]
and potential conjugation sites therein. Peptide mapping for iden-
tiﬁcation of glycopeptides in a formaldehyde-toxoided molecule
presents considerable challenge, so simpler systems are required.
This study has shown the wide range of sizes and PS/protein
loadings for TT conjugates used in licensed vaccines which have
been shown to be safe and efﬁcacious. The correlations identiﬁed
here could provide in vitro tools for further development and stud-
ies on glycoconjugates.
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